Citations

Showing 10 of 108094 citations.

The Office of Mayo Clinic Experience: A Strategy to Continuously Improve Patient Experience
Howell, Thomas G., Leighton, Jonathan A. , Poole, Kenneth , Gasparini, Robin N., Welch, Thomas, Hart, Lacey, Kilen, Andrea L., Stevens, Sheila K., Wilshusen, Laurie , Howell, Thomas G.

Mayo Clinic

NEJM Catalyst | August 17, 2022 | Volume: 3 | Issue: 9 | Pages: No page available

10.1056/cat.21.0476 Get It

Modernizing Diabetes Care Quality Measures
Jiang, David H. , Huguet, Nathalie , O’Connor, Patrick J. , Golden, Sherita Hill , McCoy, Rozalina G.

Mayo Clinic

Health Affairs | August 17, 2022 | Volume: 41 | Issue: 7 | Pages: 955-962

10.1377/hlthaff.2022.00233 | PMID 35759700 Get It

Controversy Over Liver Transplantation or Resection for Neuroendocrine Liver Metastasis
Eshmuminov, Dilmurodjon , Studer, Debora J., Schneider, Marcel , Lerut, Jan , Lo, Mary , Sher, Linda , Musholt, Thomas J. , Lozan, O , Bouzakri, Nabila , Barat, Shoma , Morris, David L. , Oehler, Helga, Husen, Peri , Rosen, Charles B. , Kim‐Fuchs, Corina , Dutkowski, Philipp , Petrowsky, Henrik , Grąt, Michał , Tanno, Lulu , Mazzaferro, Vincenzo , Clavien, Pierre‐Alain , Lehmann, Kuno , Clavien, Pierre-Alain , Lehmann, Kuno , Mazzaferro, Vincenzo , Eshmuminov, Dilmurodjon , Studer, Debora Julienne, López‐López, Víctor , Sposito, Carlo , Miceli, Rosalba , Schreckenbach, Teresa , Gores, Gregory J. , Masui, Toshihiko , Cheung, Tan To , Perren, Aurel A. , Thiis‐Evensen, Espen , Line, Pål‐Dag , Partelli, Stefano , Falconi, Massimo , Robles, R

Mayo Clinic

Annals of Surgery | August 17, 2022 | Volume: 277 | Issue: 5 | Pages: e1063-e1071

10.1097/sla.0000000000005663 | PMID 35975918 Get It

Background: In patients with neuroendocrine liver metastasis (NELM), liver transplantation (LT) is an alternative to liver resection (LR), although the choice of therapy remains controversial. In this multicenter study, we aim to provide novel insight in this dispute. Methods: Following a systematic literature search, 15 large international centers were contacted to provide comprehensive data on their patients after LR or LT for NELM. Survival analyses were performed with the Kaplan-Meier method, while multivariable Cox regression served to identify factors influencing survival after either transplantation or resection. Inverse probability weighting and propensity score matching was used for analyses with balanced and equalized baseline characteristics. Results: Overall, 455 patients were analyzed, including 230 after LR and 225 after LT, with a median follow-up of 97 months [95% confidence interval (CI): 85–110 months]. Multivariable analysis revealed G3 grading as a negative prognostic factor for LR [hazard ratio (HR)=2.22, 95% CI: 1.04–4.77, P=0.040], while G2 grading (HR=2.52, 95% CI: 1.15–5.52, P=0.021) and LT outside Milan criteria (HR=2.40, 95% CI: 1.16–4.92, P=0.018) were negative prognostic factors in transplanted patients. Inverse probability-weighted multivariate analyses revealed a distinct survival benefit after LT. Matched patients presented a median overall survival (OS) of 197 months (95% CI: 143–not reached) and a 73% 5-year OS after LT, and 119 months (95% CI: 74–133 months) and a 52.8% 5-year OS after LR (HR=0.59, 95% CI: 0.3–0.9, P=0.022). However, the survival benefit after LT was lost if patients were transplanted outside Milan criteria. Conclusions: This multicentric study in patients with NELM demonstrates a survival benefit of LT over LR. This benefit depends on adherence to selection criteria, in particular low-grade tumor biology and Milan criteria, and must be balanced against potential risks of LT.
Standardizing Pathologic Evaluation of Breast Carcinoma After Neoadjuvant Chemotherapy
Sahoo, Sunati , Krings, Gregor , Chen, Yunn‐Yi , Carter, Jodi M. , Chen, Beiyun, Guo, Hua , Reisenbichler, Emily , Fan, Fang , Wei, Shi, Khazai, Laila , Klein, Molly, Shad, Sonal , Venters, Sara J., Borowsky, Alexander D. , Symmans, W. Fraser , Ocal, Idris Tolgay, Ocal, I Tolgay, Symmans, W Fraser , Carter, Jodi , Hibshoosh, Hanina , Balassanian, Ronald

Mayo Clinic

Archives of Pathology & Laboratory Medicine | August 17, 2022 | Volume: 147 | Issue: 5 | Pages: 591-603

10.5858/arpa.2022-0021-ep | PMID 35976643 Get It

Context.— Neoadjuvant systemic therapy refers to the use of systemic agent(s) for malignancy prior to surgical treatment and has recently emerged as an option for most breast cancer patients eligible for adjuvant systemic therapy. Consequently, treated breast carcinomas have become routine specimens in pathology practices. A standard protocol has not yet been universally adopted for the evaluation and reporting of these specimens. The American Joint Committee on Cancer staging system recognizes the challenges in staging breast carcinomas after neoadjuvant treatment and provides important data points but does not currently provide detailed guidance in estimating the residual tumor burden in the breast and lymph nodes. The Residual Cancer Burden system is the only Web-based system that quantifies treatment response as a continuous variable using residual tumor burden in the breast and the lymph nodes. Objective.— To provide clarifications and guidance for evaluation and reporting of postneoadjuvant breast specimens, discuss issues with the current staging and reporting systems, and provide specific suggestions for future modifications to the American Joint Committee on Cancer system and the Residual Cancer Burden calculator. Data Sources.— English-language literature on the subject and the data from the I-SPY 2, a multicenter, adaptive randomization phase 2 neoadjuvant platform trial for early-stage, high-risk breast cancer patients. Conclusions.— This article highlights challenges in the pathologic evaluation and reporting of treated breast carcinomas and provides recommendations and clarifications for pathologists and clinicians. It also provides specific recommendations for staging and discusses future directions.
Developing a Social Media Ontology Across Otolaryngology and its Subspecialties
Flagg, Candace A. , Marinelli, John P. , Carlson, Matthew L. , Kezirian, Eric J. , Dion, Gregory R. , Abel, Kathryn M. Van , Bowe, Sarah N. , Van Abel, Kathryn M , Choby, Garret , Bowe, Sarah N , Kezirian, Eric J , Dion, Greg , Choby, Garret , Hamilton, Grant

Mayo Clinic

The Laryngoscope | August 17, 2022 | Volume: 133 | Issue: 7 | Pages: 1595-1599

10.1002/lary.30345 | PMID 37294045 Get It

ObjectiveTo determine how social media is used in the dissemination of new information within otolaryngology, and to emphasize the importance of standardizing Twitter hashtag use.MethodsBased on the 2019 SCImago journal rankings, the Twitter posts from the accounts of the top three journals covering each otolaryngology subspecialty were reviewed from August 1, 2020 to May 1, 2021. Twitter posts from the primary otolaryngology‐related academic societies were also reviewed during this timeframe. A list of hashtags was generated based on a combination of the most common otolaryngologic procedures and most commonly used hashtags in the social media space. This list was then crowd‐sourced with 10 fellowship‐trained otolaryngologists for each subspecialty.ResultsHashtag use among key stakeholders in the otolaryngology social media space varies considerably. For instance, #HNSCC, #HeadAndNeckSquamousCellCarcinoma, #HeadAndNeckCancer, #HeadAndNeckCancers, #OropharyngealCancer, #OropharynxCancer, #OralCancer, and #OPSCC were all commonly used hashtags to identify posts discussing oropharyngeal squamous cell carcinoma. #HeadAndNeckCancer and #HNSCC were most popular and used in a total of 85 and 65 tweets, respectively. #HeadAndNeckCancer was found alone in 32 out of 85 tweets (38%), whereas #HNSCC was found alone in 27 out of 65 tweets (42%). A standardized hashtag ontology covering all subspecialties within otolaryngology is proposed herein.ConclusionsAdoption of a standardized social media ontology within otolaryngology will improve information dissemination across all key stakeholders. Laryngoscope, 133:1595–1599, 2023
Evidence-Based Clinical Practice Guidelines for Laser-Assisted Drug Delivery
Labadie, Jessica G. , Worley, Brandon , Kang, Bianca Y. , Rakita, Uros , Rigali, Sarah , Arndt, Kenneth A., Brauer, Jeremy A., Chandra, Sunandana , Didwania, Aashish , DiGiorgio, Catherine M., Donelan, Mattias, Dover, Jeffrey S. , Geronemus, Roy G. , Goldman, Mitchel P. , Hruza, George J. , Ibrahimi, Omar A. , Kauvar, Arielle N.B. , Kelly, Kristen M. , Krakowski, Andrew C. , Miest, Rachel Y. , Orringer, Jeffrey S. , Ozog, David , Ross, E. Victor , Shumaker, Peter R. , Sobanko, Joseph F. , Suozzi, Kathleen C. , Taylor, Mark B., Teng, Joyce , Uebelhoer, Nathan S., Waibel, Jill , Wanner, Molly, Ratchev, Ina, Poon, Emily , Miller, Corinne H. , Alam, Murad , Miest, Rachel, Kelly, Kristen M , Ibrahim, Sarah A. , Bernstein, Eric F. , Galadari, Hassan , Hædersdal, Merete , Christensen, Rachel E. , Alam, Murad

Mayo Clinic

JAMA Dermatology | August 17, 2022 | Volume: 158 | Issue: 10 | Pages: 1193

10.1001/jamadermatol.2022.3234 | PMID 35976634 Get It

Importance Laser-assisted drug delivery (LADD) is used for various medical and cosmetic applications. However, there is insufficient evidence-based guidance to assist clinicians performing LADD. Objective To develop recommendations for the safe and effective use of LADD. Evidence Review A systematic literature review of Cochrane Central Register of Controlled Trials, Embase, and MEDLINE was conducted in December 2019 to identify publications reporting research on LADD. A multidisciplinary panel was convened to draft recommendations informed by the systematic review; they were refined through 2 rounds of Delphi survey, 2 consensus meetings, and iterative review by all panelists until unanimous consensus was achieved. Findings Of the 48 published studies of ablative fractional LADD that met inclusion criteria, 4 were cosmetic studies; 21, oncologic; and 23, medical (not cosmetic/oncologic), and 6 publications of nonablative fractional LADD were included at the request of the expert panel, producing a total of 54 studies. Thirty-four studies (63.0%) were deemed to have low risk of bias, 17 studies (31.5%) had moderate risk, and 3 (5.5%) had serious risk. The key findings that informed the guidelines developed by the expert panel were as follows: LADD is safe in adults and adolescents (≥12 years) with all Fitzpatrick skin types and in patients with immunosuppression; it is an effective treatment for actinic keratosis, cutaneous squamous cell carcinoma in situ, actinic cheilitis, hypertrophic scars, and keloids; it is useful for epidermal and dermal analgesia; drug delivery may be increased through the application of heat, pressure, or occlusion, or by using an aqueous drug solution; laser settings should be selected to ensure that channel diameter is greater than the delivered molecule; antibiotic prophylaxis is not recommended, except with impaired wound healing; antiviral prophylaxis is recommended when treating the face and genitalia; and antifungal prophylaxis is not recommended. The guideline’s 15 recommendations address 5 areas of LADD use: (I) indications and contraindications; (II) parameters to report; (III) optimization of drug delivery; (IV) safety considerations; and (V) prophylaxis for bacterial, viral, and fungal infections. Conclusions and Relevance This systematic review and Delphi consensus approach culminated in an evidence-based clinical practice guideline for safe and effective use of LADD in a variety of applications. Future research will further improve our understanding of this novel treatment technique.
CD38 as a multifaceted immunotherapeutic target in CLL
Paulus, Aneel , Malavasi, Fabio , Chanan‐Khan, Asher , Malavasi, Fabio , Paulus, Aneel

Mayo Clinic

Leukemia & Lymphoma | August 17, 2022 | Volume: 63 | Issue: 10 | Pages: 2265-2275

10.1080/10428194.2022.2090551 | PMID 35975791 Get It

Corticosteroids for patients with vestibular neuritis: An evidence synthesis for guidelines for reasonable and appropriate care in the emergency department
Silva, Lucas Oliveira J. e , Khoujah, Danya , Naples, James G. , Edlow, Jonathan A. , Gerberi, Dana , Carpenter, Christopher R. , Bellolio, Fernanda , Oliveira J E Silva, Lucas , Bellolio, M Fernanda , Carpenter, Christopher R , Khoujah, Danya

Mayo Clinic

Academic Emergency Medicine | August 17, 2022 | Volume: 30 | Issue: 5 | Pages: 531-540

10.1111/acem.14583 | PMID 35975654 Get It

AbstractBackgroundA short course of corticosteroids is among the management strategies considered by specialists for the treatment of vestibular neuritis (VN). We conducted an umbrella review (systematic review of systematic reviews) to summarize the evidence of corticosteroids use for the treatment of VN.MethodsWe included systematic reviews of randomized controlled trials (RCTs) and observational studies that evaluated the effects of corticosteroids compared to placebo or usual care in adult patients with acute VN. Titles, abstracts, and full texts were screened in duplicate. The quality of reviews was assessed with the A MeaSurement Tool to Assess systematic Reviews (AMSTAR‐2) tool. The Grading of Recommendations, Assessment, Development and Evaluation (GRADE) assessment was used to rate certainty of evidence. No meta‐analysis was performed.ResultsFrom 149 titles, five systematic reviews were selected for quality assessment, and two reviews were of higher methodological quality and were included. These two reviews included 12 individual studies and 660 patients with VN. In a meta‐analysis of two RCTs including a total of 50 patients, the use of corticosteroids (compared to placebo) was associated with higher complete caloric recovery (risk ratio 2.81, 95% confidence interval [CI] 1.32 to 6.00, low certainty). It is very uncertain whether this translates into clinical improvement as shown by the imprecise effect estimates for outcomes such as patient‐reported vertigo or patient‐reported dizziness disability. There was a wide CI for the outcome of dizziness handicap score (one study, 30 patients, 20.9 points in corticosteroids group vs. 15.8 points in placebo, mean difference +5.1, 95% CI −8.09 to +18.29, very low certainty). Higher rates of minor adverse effects for those receiving corticosteroids were reported, but the certainty in this evidence was very low.ConclusionsThere is limited evidence to support the use of corticosteroids for the treatment of VN in the emergency department.
Efficacy and safety of vibegron for the treatment of irritable bowel syndrome in women: Results of a randomized, double‐blind, placebo‐controlled phase 2 trial
Lacy, Brian E. , King, Jennifer , Shortino, Denise, Schaumburg, Chris S., Haag‐Molkenteller, Cornelia, Chey, William D. , Lacy, Brian , Lacy, Brian E. , King, Jennifer

Mayo Clinic

Neurogastroenterology & Motility | August 17, 2022 | Volume: 34 | Issue: 12 | Pages: No page available

10.1111/nmo.14448 | PMID 35975404 Get It

AbstractBackgroundPreclinical and clinical studies suggest that β3‐adrenergic receptor activation may be a novel target for treating abdominal pain and gastrointestinal motility dysfunction in patients with irritable bowel syndrome (IBS). This proof‐of‐concept study evaluated the efficacy and safety of the β3‐adrenergic agonist vibegron in treating IBS‐related pain.MethodsAdult women with predominant‐diarrhea IBS (IBS‐D) or with mixed diarrhea/constipation (IBS‐M), diagnosed using Rome IV criteria, were randomized 1:1 to receive once‐daily vibegron 75 mg or placebo for 12 weeks. The primary endpoint was the percentage of patients with IBS‐D considered abdominal pain intensity (API) weekly responders, defined as ≥30% reduction from baseline at week 12 in mean weekly worst abdominal pain over 24 hours using the API score. Patients completed a pain diary at baseline and at weeks 2, 4, 8, and 12. Safety was assessed by adverse events (AEs) in the overall IBS population.Key ResultsOf the 222 patients with IBS randomized (vibegron, N = 111; placebo, N = 111), 85% completed the trial. There was no significant difference in the percentage of patients with IBS‐D (vibegron, N = 66; placebo, N = 63) considered API weekly responders with vibegron vs. placebo (p = 0.8222) after 12 weeks. The incidence of AEs was comparable between treatment groups (33.3% each), with equal rates of worsening IBS symptoms (2.7% each).Conclusions and InferencesIn women with IBS‐D, vibegron was not associated with significant improvement in the percentage of API weekly responders. Vibegron was generally safe and well tolerated and, in particular, did not worsen IBS symptoms vs. placebo.
The Magnetic Resonance Imaging Pattern of the Lesions Caused by Knee Overuse in the Pediatric Population
Djuričić, Goran , Milojkovic, Djordje, Mijucic, Jovana , Dučić, Siniša , Bukva, Bojan , Radulović, Marko , Milčanović, Petar, Milić, Nataša , Milic, N , Rajović, Nina

Mayo Clinic

Medicina | August 17, 2022 | Volume: 58 | Issue: 8 | Pages: 1107

10.3390/medicina58081107 | PMID 36013574 Get It

Background and Objectives: Excessive use of the knee in patients with immature locomotor systems leads to a whole spectrum of morphological changes with possible consequences in adulthood. This study aimed to examine the morphological pattern in magnetic resonance imaging (MRI) that is associated with recurrent pain due to increased physical activity in children. Materials and Methods: This was a retrospective study conducted among pediatric patients treated at the University Children’s Hospital in Belgrade in 2018 and 2019. MRI findings of patients who reported recurrent pain in the knee joint during physical activity and who were without any pathological findings on both clinical examination and knee radiographs were included in the study. Results: MRI findings of 168 patients (73 boys and 95 girls, mean age 14.07 ± 3.34 years) were assessed. Meniscus and cartilage lesions were the most commonly detected morphological findings: meniscus lesions in 49.4%, cartilage ruptures in 44.6%, and cartilage edema in 26.2% of patients. The medial meniscus was more often injured in girls (p = 0.030), while boys were more prone to other joint injuries (p = 0.016), re-injury of the same joint (p = 0.036), bone bruises (p < 0.001), and ligament injuries (p = 0.001). In children older than 15 years, tibial plateau cartilage edema (p = 0.016), chondromalacia patellae (p = 0.005), and retropatellar effusion (p = 0.011) were detected more frequently compared to younger children. Conclusions: Children reporting recurrent knee pain due to increased physical activity, without any detected pathological findings on clinical examination and knee radiography, may have morphological changes that can be detected on MRI. Timely diagnosis of joint lesions should play a significant role in preventing permanent joint dysfunction in the pediatric population as well as in preventing the development of musculoskeletal diseases in adulthood.